|22nd December 2020||Management Inc. Opaleye||496,277||Open or private purchase||$8.06||$3,999,992.62|
|22nd December 2020||Management Inc. Opaleye||657||Open or private purchase||$5.19||$3,412.98|
|22nd December 2020||Management Inc. Opaleye||15,900||Open or private purchase||$5.19||$82,597.32|
|21st December 2020||Management Inc. Opaleye||51,400||Open or private purchase||$5.24||$269,305.16|
|21st December 2020||Management Inc. Opaleye||2,059||Open or private purchase||$5.24||$10,787.92|
|18th December 2020||Management Inc. Opaleye||35,000||Open or private purchase||$5.31||$185,941.00|
|18th December 2020||Management Inc. Opaleye||1,400||Open or private purchase||$5.31||$7,437.64|
|10th December 2020||John Gordon Freund||56,327||Other acquisition or disposition||$0.00|
|10th December 2020||John Gordon Freund||118,735||Other acquisition or disposition||$0.00|
|3rd December 2020||John Gordon Freund||47,886||Open or private sale||$23.39||$1,120,197.20|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Proteon Therapeutics, Inc. engages in the research and development of biopharmaceutical products. It produces and commercializes vonapanitase for the treatment of renal and vascular disease. The company was founded by F. Nicholas Franano and William P. Whitaker in 2001.